A 32-year-old man from Delhi presents with a 4-month history of productive cough, fever, and weight loss. Chest X-ray shows left upper lobe infiltrates. Sputum smear microscopy is positive for acid-fast bacilli. He was treated with standard first-line anti-TB drugs (HRZE) for 2 months but showed no clinical improvement. Drug susceptibility testing confirms resistance to both isoniazid and rifampicin. What is the drug of choice for initiating treatment in this patient with MDR-TB?

Explanation

## MDR-TB Treatment Regimen **Key Point:** MDR-TB (resistant to both isoniazid and rifampicin) requires a prolonged, intensive regimen combining newer and repurposed drugs. The standard MDR-TB regimen includes a fluoroquinolone, an injectable second-line agent, and a third drug. ### Current WHO/NTEP Recommended MDR-TB Regimen The preferred first-line MDR-TB regimen consists of: | Component | Drug | Duration | Role | |-----------|------|----------|------| | Fluoroquinolone | Levofloxacin or moxifloxacin | 20 months | Core agent, excellent lung penetration | | Injectable agent | Amikacin or streptomycin | 5–7 months (intensive phase) | Bactericidal, rapid sputum conversion | | Third agent | Ethionamide or prothionamide | 20 months | Additional coverage | | Fourth agent (optional) | Pyrazinamide or ethambutol | 20 months | Adjunctive | **High-Yield:** The regimen is typically **5–7 months intensive phase** (fluoroquinolone + injectable + ethionamide ± pyrazinamide) followed by **13–14 months continuation phase** (fluoroquinolone + ethionamide ± pyrazinamide). ### Mechanism of Action of Second-Line Drugs - **Fluoroquinolones** (levofloxacin, moxifloxacin): Inhibit DNA gyrase; excellent intracellular penetration and lung tissue concentration. - **Aminoglycosides** (amikacin, streptomycin): Inhibit protein synthesis; bactericidal; rapid early sputum conversion. - **Ethionamide/Prothionamide**: Prodrugs activated by mycobacterial enzymes; inhibit mycolic acid synthesis. **Clinical Pearl:** Moxifloxacin has superior mycobacterial activity compared to levofloxacin but is more expensive; levofloxacin remains the standard in resource-limited settings like India. **Warning:** Monotherapy with any single agent (including moxifloxacin alone) is contraindicated in MDR-TB — it leads to rapid development of additional resistance and treatment failure. ### Why This Regimen? The three-drug combination (fluoroquinolone + injectable + ethionamide) provides: 1. Synergistic bactericidal activity 2. Rapid sputum conversion (injectable phase) 3. Prevention of acquired resistance during treatment 4. Acceptable toxicity profile in resource-limited settings [cite:NTEP TB India Guidelines 2023, WHO TB Report 2023]